Durvalumab Combined With Pemetrexed-Based Chemotherapy in Trial-Ineligible Patients With Mesothelioma: A Brief Report by Ibiayi Dagogo-Jack, MD, Aubrey Lasko, PharmD, Elizabeth A. Krueger, NP, Kitman Tsang, NP, Revati Rao, MD, Grace Hambelton, BA, Subba R. Digumarthy, MD

Subjects: Get full text

Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice by Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Akihiro Morishita, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto, Tetsuji Takayama

Subjects: “…durvalumab…”
Get full text

Olaparib monotherapy or combination therapy in lung cancer: an updated systematic review and meta- analysis by Sajjad Hajihosseini, Ehsan Emami, Seyed Amirali Zakavi, Parnia Jochin, Mehregan Shahrokhi, Sahar Khoshravesh, Mitra Goli, Mohaddeseh Belbasi, Gisou Erabi, Niloofar Deravi

Subjects: Get full text

Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab by Alfredo S. Golemba, MD, Astor A. Aguirre Santamaría, MD, Raúl E. García Tolosa, MD

Subjects: Get full text

Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003) by Hidenobu Ishii, MD, PhD, Koichi Azuma, MD, PhD, Yuta Yamanaka, MD, Hiroshige Yoshioka, MD, PhD, Yukihiro Toi, MD, Naoki Shingu, MD, Katsuhiko Naoki, MD, PhD, Masaki Okamoto, MD, PhD, Yuko Tsuchiya-Kawano, MD, PhD, Taishi Harada, MD, Hiroyuki Inoue, MD, PhD, Hiroshi Ishii, MD, PhD, Kazunori Tobino, MD, PhD, Chiho Nakashima, MD, PhD, Yoshifusa Koreeda, MD, Yasushi Hisamatsu, MD, Shinsuke Tsumura, MD, Takashi Inagaki, MD, Keiko Mizuno, MD, PhD, Takayuki Shimose, MMath, Isamu Okamoto, MD, PhD

Subjects: Get full text

Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) in patients with unresectable biliary tract cancer treated with gemcitabine, cisplatin, and durvalumab by Satoshi Mii, Hiroyuki Kato, Takeshi Takahara, Masayuki Kojima, Yutaro Kato, Zenichi Morise, Akihiko Horiguchi, Koichi Suda

Subjects: Get full text

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab by Narek Shaverdian, Maria Thor, Annemarie F. Shepherd, Michael D. Offin, Andrew Jackson, Abraham J. Wu, Daphna Y. Gelblum, Ellen D. Yorke, Charles B. Simone II, Jamie E. Chaft, Matthew D. Hellmann, Daniel R. Gomez, Andreas Rimner, Joseph O. Deasy

Subjects: “…durvalumab…”
Get full text

Adverse drug reaction to tremelimumab and durvalumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database by Wei Fan Sui, Yu Xin Duan, Ze Feng Cai, Yi Mao Xia, Jian Yun Li, Jian Hua Fu

Subjects: Get full text

Development of shellfish allergy after exposure to dual immune checkpoint blockade by Zachary J Brown, Bernd Heinrich, Tim F Greten

Subjects: Get full text

The burden and clinical trajectory of immune checkpoint inhibitor-induced endocrinopathies: an 8-year experience by Fateen Ata, Adeel Ahmad Khan, Emad Algorani, Amr Faisal Musaed Alsharafi, Reham Abo Shdid, Mohammad Nofal, Ayman R. Ibrahim, Loai Abdullah, Khalil Youssef El Annan, Tareq Emad Hawash Al-Bkoor, Kakil Ibrahim Rasul, Tarik Elhadd, Haval Surchi

Subjects: Get full text

Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐CD73/anti‐PD‐L1 immunotherapy in arm A of the NSGO‐OV‐UMB1/ENGOT‐OV3... by Luka Tandaric, Annika Auranen, Katrin Kleinmanns, René DePont Christensen, Liv Cecilie Vestrheim Thomsen, Cara Ellen Wogsland, Emmet McCormack, Johanna Mäenpää, Kristine Madsen, Karen Stampe Petersson, Mansoor Raza Mirza, Line Bjørge

Subjects: Get full text

Successful stent removal after chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer with airway stenosis: A report of three cases by Yuki Takigawa, Ken Sato, Daisuke Minami, Kenichiro Kudo, Shoichiro Matsumoto, Miho Fujiwara, Takeru Ichikawa, Tomoyoshi Inoue, Suzuka Matsuoka, Hiromi Watanabe, Akiko Sato, Hiroyasu Shoda, Nobuhisa Ishikawa, Keiichi Fujiwara, Takuo Shibayama

Subjects: Get full text

Integrating Immunotherapy With Targeted Therapy: Evaluating Efficacy in NSCLC Treatment Through Computational Analysis of Gene Regulatory Networks by Pranabesh Bhattacharjee, Aditya Lahiri, Tanmay Sindhwani, Norman Peter Reeves, Aniruddha Datta

Subjects: Get full text

PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first... by Andrei Gurau, Suguru Yamauchi, Kaitlyn Ecoff, Kristen P. Rodgers, James R. Eshleman, Charles Conover Talbot Jr, Peng Huang, Joshua Choi, Patrick M. Forde, Valsamo Anagnostou, Malcolm Brock, Yuping Mei

Subjects: Get full text

Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Rec... by Anthony M. Brade, Houda Bahig, Andrea Bezjak, Rosalyn A. Juergens, Charmaine Lynden, Nicolas Marcoux, Barbara Melosky, Devin Schellenberg, Stephanie Snow

Subjects: Get full text

Clinical outcomes of transarterial chemoembolization combined with durvalumab for advanced and metastatic biliary tract cancer by Yuefeng Hu, Jian Wei, Xuedong Sun, Guang Chen, Tianhao Su, Zeran Yang, Xu Lu, Long Jin

Subjects: Get full text

Higher Absolute Lymphocyte Counts and Lower Des‐γ‐Carboxyprothrombin Levels After Treatment Initiation Are Associated With the Clinical Efficacy of Tremelimumab Plus Durvalumab Com... by Yuta Inoue, Yoshihiko Yano, Saeko Kushida, Seiya Hirohata, Seitetsu Yoon, Eiichiro Yasutomi, Hirotaka Hirano, Soo Ki Kim, Ryutaro Yoshida, Yoshihide Ueda, Kenji Momose, Hiroki Hayashi, Takuo Kado, Katsuhisa Nishi, Hidenori Tanaka, Tomomitsu Matono, Atsushi Yamamoto, Hiroshi Tei, Chiharu Nishioka, Yosuke Yagi, Shoji Tamura, Tatsuya Sakane, Mayumi Ehara, Miki Kawano, Jun Kitadai, Takanori Matsuura, Yuuki Shiomi, Shohei Komatsu, Takumi Fukumoto, Toshifumi Tada, Yuzo Kodama

Subjects: Get full text

Durvalumab induced immune-related agranulocytosis after conversion surgery in a patient with intrahepatic cholangiocarcinoma: a case report by Yoshihito Kitamura, Seiichi Shimizu, Shintaro Kuroda, Naruhiko Honmyo, Ryosuke Nakano, Hiroshi Sakai, Hiroyuki Tahara, Masahiro Ohira, Kentaro Ide, Tsuyoshi Kobayashi, Tatsuo Ichinohe, Hideki Ohdan

Subjects: Get full text

A pharmacovigilance analysis of post-marketing safety of durvalumab by An-Ju Tan, Wan-Ying Liu, Jun-Li Lu, Qing-Ying Tan, Yu Yan, Dun-Chang Mo

Subjects: Get full text

First-line durvalumab plus platinum–etoposide in Japanese patients with extensive-stage small-cell lung cancer by Eisuke Mochizuki, Shun Matsuura, Naoki Koshimizu, Suguru Kojima, Shogo Sakurai, Satoshi Kishimoto, Mitsuru Niwa, Masayuki Watanuki, Ryunosuke Inaba, Sho Takuma, Yusuke Inoue, Masato Karayama, Naoki Inui, Takafumi Suda

Subjects: Get full text